鍏充簬鎯犲皵閲�<\/b>®<\/sup><\/b>锛堣帿鏍煎埄鐝犲崟鎶楋級<\/b><\/p> \n
鎯犲皵閲�®<\/sup><\/b>鏄竴娆惧悓绫婚鍒涗汉婧愬寲鍗曞厠闅嗘姉浣擄紙mAb锛夛紝鏃ㄥ湪涓嶤-C瓒嬪寲鍥犲瓙鍙椾綋4锛圕CR4锛夌浉缁撳悎銆傛儬灏旈噾®<\/sup><\/b>涓嶤CR4缁撳悎鍚庯紝浼氬湪浜轰綋鍏嶇柅绯荤粺涓縺娲绘洿澶氱殑鍏嶇柅缁嗚優锛岃繘鑰岀牬鍧忕檶缁嗚優[7]<\/span><\/sup>銆傛儬灏旈噾®<\/sup><\/b>浣跨敤鍗忓拰楹掗簾涓撴湁鐨凱OTELLIGENT®<\/sup><\/b>鎶€鏈紝鍙寮轰汉浣撳娌荤枟鐨勮嚜鐒跺厤鐤弽搴旓紝浠庤€屾彁楂樺鐧岀粏鑳炵殑鏉€浼ゅ姏銆侳DA宸叉巿浜堟儬灏旈噾®<\/sup><\/b>绐佺牬鎬х枟娉曞拰瀛ゅ効鑽瀹�[19],[20<\/span>]<\/sup>銆傛澶栵紝鎯犲皵閲�®<\/sup><\/b>杩樹簬2016骞磋娆х洘濮斿憳浼氾紙EC锛夋巿浜堝鍎胯嵂璁ゅ畾[21]<\/span><\/sup>銆傛儬灏旈噾®<\/sup><\/b>鏄涓篃鏄�鍞竴<\/span>鍦ㄤ腑鍥藉拰涓栫晫鍏朵粬鍦板尯鑾锋壒鐨勯澏鍚慍CR4鐨勭敓鐗╁埗鍓�[22]<\/span><\/sup>銆�<\/p> \n
*浼忕珛璇轰粬鏄編鍥紽DA鎵瑰噯鐢ㄤ簬娌荤枟钑堟牱鑲夎娊鑲垮拰濉炴墡閲岀患鍚堝緛鐨勮嵂鐗╋紝鐩墠灏氭湭鍦ㄤ腑鍥借幏鎵�<\/p> \n
鍙傝€冩枃鐚�<\/b><\/p> \n
[1] Until July 2022<\/span>, the data source: Ding Xiang Yuan database.
<\/sup>[2] Placeholder (To be updated with NMPA approval news release)
<\/sup>[3] Kim YH, Bagot M, Pinter-Brown L, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol<\/i>. 2018;19(9):1192-1204.
<\/sup>[4] Ferenczi K, Fuhlbrigge RC, Pinkus J, et al. Increased CCR4 expression in cutaneous T cell lymphoma. J Invest Dermatol<\/i>. 2002;119:1405-10.
<\/sup>[5] Yoshie O, et al. Frequent Expression of CCR4 in Adult T-Cell Leukemia and Human T-cell Leukemia Virus Type 1-transformed T cells. Blood<\/i>. 2002;99(5):1505-11.
<\/sup>[6] Ishida T, et al. Clinical Significance of CCR4 Expression in Adult T-cell Leukemia\/Lymphoma: Its Close Association With Skin Involvement and Unfavorable Outcome. Clin Cancer Res<\/span><\/i>. 2003;9:3625-34.
<\/sup>[7] Duvic M, et al. Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential. Ther Adv Hematol<\/i>. 2016;7(3):171-174.
<\/sup>[8] Willemze R, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood<\/i>. 2019;133(16):1703-1714.
<\/sup>[9] Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood<\/i>. 2007;110(6):1713-22.
<\/sup>[10] Orphanet: Prevalence and incidence of rare diseases: Bibliographic data. Available from: https:\/\/www.orpha.net\/orphacom\/cahiers\/docs\/GB\/Prevalence_of_rare_diseases_by_decreasing_prevalence_or_cases.pdf<\/a>. Last accessed: June 2020<\/span>.
<\/sup>[11] Orphanet: Mycosis Fungoides. Available from: https:\/\/www.orpha.net\/consor\/cgi-bin\/OC_Exp.php?Lng=GB&Expert=2584<\/a>. <\/u>Last Accessed: June 2020<\/span>.
<\/sup>[12] Orphanet: Sézary syndrome. Available from: https:\/\/www.orpha.net\/consor\/cgi-bin\/OC_Exp.php?Expert=3162<\/a>. Last Accessed: June 2020<\/span>.
<\/sup>[13] Haun P, et al. Fast Facts : Diagnosing Cutaneous T-Cell Lymphoma. Karger Publishing<\/i>. 2016.
<\/sup>[14] Cutaneous Lymphoma Foundation, Lymphoma Action and Lymphoma Coalition Europe. Cutaneous lymphoma 鈥� a patient's guide. 2019. Available from: https:\/\/lymphoma-action.org.uk\/sites\/default\/files\/media\/documents\/2019-06\/Cutaneous%20lymphoma%20-%20patient%26%23039%3Bs%20guide%20-%20English%20language%20source%20document%20-%20final%20version%20for%20publication%20-%20April%202019.pdf<\/a>. Last accessed: June 2020<\/span>.
<\/sup>[15] CL Foundation: A Patient's Guide. Available from: https:\/\/www.clfoundation.org\/sites\/default\/files\/2018-04\/a_patients_guide.pdf<\/a>. Last Accessed: 18 November 2019<\/span>.
<\/sup>[16] Scarisbrick JJ, Prince M, Vermeer MH, et al. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. J Clin Oncol<\/i>. 2015;33(32):3766-3773.
<\/sup>[17] Kim YH, Bagot M, Zinzani PL et al. Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study. Blood. 2019;134 (1):5300.
<\/sup>[18] Clin Lymphoma Myeloma Leuk. 2021 Feb; 21(2):97-105
<\/sup>[19] Search Orphan Drug Designations and Approvals (fda.gov). Available from https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=322010<\/a>. Last accessed: July 2022<\/span>.
<\/sup>[20] FDA approves treatment for two rare types of non-Hodgkin lymphoma. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-treatment-two-rare-types-non-hodgkin-lymphoma<\/a>. Last accessed: July 2022<\/span>.
<\/sup>[21] EU\/3\/16\/1756: Orphan designation for the treatment of cutaneous T-cell lymphoma. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu3161756. Last accessed: July 2022<\/span>.<\/sup><\/p> \n